Diagnosis
Eligibility depends on the cancer type, how many prior lines of treatment have failed, organ function and the target antigen on the tumor. CD19, BCMA and Claudin18.2 status are confirmed by pathology review before anything else.
Treatment Options
CAR-T involves leukapheresis, a two-to-four-week manufacturing window, lymphodepleting chemotherapy and infusion, followed by roughly ten to fourteen days of inpatient monitoring. China offers both approved products and clinical-trial access to experimental targets.
Typical Costs in China
Prices are reference ranges; final quotes come from the hospital after case review.
Top Hospitals for CAR-T Cell Therapy
Frequently Asked Questions
Which hospital offers CAR-T therapy in China?
Leading centres include the Cancer Hospital of CAMS and Peking University People's Hospital (Beijing), Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center (Guangzhou), and West China Lecheng Hospital in the Hainan Lecheng zone. Foshan Fosun Chancheng Hospital lists CAR-T among its oncology services. A case review confirms which of these can take your case.
How much does CAR-T therapy cost in China?
Reference ranges: approved CD19 or BCMA CAR-T runs roughly $89,000–$170,000 for the drug plus the full course, and clinical trial participation typically $30,000–$80,000. Confirm whether a quote includes tocilizumab, ICU standby and the full monitoring period, which are sometimes billed separately.
Is CAR-T a cure?
No. CAR-T has produced durable remissions in some blood cancers, but it is not a cure and it is not suitable for everyone. Response figures are reported at group level, and the treatment carries real risks including cytokine release syndrome and neurological toxicity.
Considering treatment for CAR-T Cell Therapy?
Tell us your diagnosis, scans and timing. We'll match you with the right Grade 3A hospital, compare likely costs, and outline the next practical step — free, no commitment.
Start Free Case Review →